The Impact of Residual Symptoms in Major Depression
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The current definition of remission from major depressive disorder does not fully take into account all aspects of patient recovery. Residual symptoms of depression are very common in patients who are classified as being in remission. Patients with residual symptoms are at increased risk of functional and interpersonal impairments, and are at high risk for recurrence of depression. This article discusses the incidence of residual symptoms of depression, as well as the risks and consequences of these symptoms, and will review the state of current treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Even so, only 30% of patients in most clinical trials of antidepressant monotherapy achieve this limited state of remission [1].”
BackgroundBelmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“Remission, on the other hand, is conceptualized as a return to a state of normal functioning and minimal symptomatology [5].”
BackgroundSheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382 · cited 1×
“These patients are at increased risk of developing treatment-resistant depression [55], and there is evidence that chronic or recurrent major depression is associated with morphometric brain changes, including bilateral reduction in hippocampal volume [56].”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Place of chronic insomnia in the course of depressive and anxiety disorders
Ohayon, M. M., & Roth, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00052-3 · Cited by 873 · cited 1×
“The residual symptoms of insomnia and other sleep disturbances are independent predictors of recurrence of MDD [29–31].”
BackgroundResidual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 2×
“Another study followed patients in remission from MDD for 10 months and found that 76% of patients with residual symptoms relapsed, compared to only 25% of those who were symptom-free [21].”
BackgroundReport by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 1×
“The actual cut-off score between response and remission is somewhat arbitrary [9], and depressed patients themselves may consider symptom resolution a less important indicator of remission than features such as optimism and self-confidence [10].”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Electroconvulsive Therapy for Depression
Lisanby, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmct075234 · Cited by 503
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“In one study of 108 patients who had achieved remission, 26% had one residual symptom, and 57% had 2 or more symptoms [15] (Figure 1).”
BackgroundJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
Judd, L. L., Akiskal, H. S., & Paulus, M. P. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00055-4 · Cited by 444
How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.148 · Cited by 431 · cited 1×
“The actual cut-off score between response and remission is somewhat arbitrary [9], and depressed patients themselves may consider symptom resolution a less important indicator of remission than features such as optimism and self-confidence [10].”
BackgroundKeller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 5×
“Importantly, these criteria do not require that patients be completely asymptomatic to be considered in remission [3, 7].”
BackgroundMethodInfluentialSix-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299 · cited 3×
“It is not clear if these symptoms are best categorized as trait or state dependent: are these stable, premorbid personality characteristics, or rather symptoms of depression that can resolve when MDD is entirely resolved? There is evidence to support both of these positions [47,48].”
BackgroundCognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266 · cited 1×
“Many residual symptoms, including anxiety, are also frequently prodromal symptoms in the same patients [13,40], and as such can be useful as harbingers of recurrence of MDD.”
BackgroundCarney, C. E., Segal, Z. V., Edinger, J. D., & Krystal, A. D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0211 · Cited by 265 · cited 1×
“Common residual somatic symptoms include backache, muscle ache, stomach aches and joint pain [14,25–27].”
Background(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1046 · Cited by 252 · cited 1×
“Residual symptoms are a predictor of relapse regardless of whether the patient was treated with medications or with psychotherapy [23].”
BackgroundA double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Residual symptoms at remission from depression: Impact on long-term outcome
Kennedy, N., & Paykel, E. S. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00054-5 · Cited by 199 · cited 1×
“The ability to participate in leisure activities and relationships are also impaired in patients with residuals symptoms of MDD, and it is not surprising that marital relationships suffer as well [54].”
BackgroundHorsten, M. (2000) · European Heart Journal · doi:10.1053/euhj.1999.2012 · Cited by 196
Course of illness in depressive and bipolar disorders: Naturalistic study, 1994–1999
Kessing, L. V., Hansen, M. G., & Andersen, P. K. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.5.372 · Cited by 191
KENNEDY, N., ABBOTT, R., & PAYKEL, E. S. (2003) · Psychological Medicine · doi:10.1017/s003329170300744x · Cited by 165
Pintor, L., Torres, X., Navarro, V., Matrai, S., & Gastó, C. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.11.008 · Cited by 76
Heterogeneity among depressed outpatients considered to be in remission
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2006.10.005 · Cited by 53
Cited by
Treating major depression with yoga: A prospective, randomized, controlled pilot trial
Prathikanti, S., Rivera, R., Cochran, A., Tungol, J. G., Fayazmanesh, N., & Weinmann, E. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173869 · Cited by 157
Hengartner, M. P., & Plöderl, M. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111600 · Cited by 114
Chiesa, A., Castagner, V., Andrisano, C., Serretti, A., Mandelli, L., Porcelli, S., & Giommi, F. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.003 · Cited by 89
Jain, S., Gupta, S., Li, V. W., Suthoff, E., & Arnaud, A. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04165-x · Cited by 53
Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35
Metadata
- Authors
- Israel, J. A.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2010-08-03
- Volume
- 3
- Issue
- 8
- Pages
- 2426-2440
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2101624688
- Cited by
- 67
- References
- 28
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.